The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
文摘
METex14 alterations occur in 2–3% of lung cancers. MET TKIs have shown preliminary clinical benefit in patients with METex14+ NSCLC. Targeting of METex14 alterations is expected to lead to the approval of MET TKIs in NSCLC. Drug switching and/or combination therapy may be required to target resistance.